A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Despite years of active research, there are still no approved medications for the treatment of cocaine dependence. Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled conditions, and the current study assessed whether modafinil would improve clinical outcome in cocaine-dependent patients receiving standardized psychosocial treatment. This was a randomized, double-blind, placebo-controlled trial conducted at a university outpatient center (from 2002 to 2003) on a consecutive sample of 62 (predominantly African American) cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. After screening, eligible patients were randomized to a single morning dose of modafinil (400 mg), or matching placebo tablets, for 8 weeks while receiving manual-guided, twice-weekly cognitive behavioral therapy. The primary efficacy measure was cocaine abstinence based on urine benzoylecgonine levels. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more BE-negative urine samples (p=0.03) over the 8-week trial when compared to placebos, and were more likely to achieve a protracted period (> or =3 weeks) of cocaine abstinence (p=0.05). There were no serious adverse events, and none of the patients failed to complete the study as a result of adverse events. This study provides preliminary evidence, which should be confirmed by a larger study, that modafinil improves clinical outcome when combined with psychosocial treatment for cocaine dependence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with severe chronic health concerns tend to have a slower response to treatment with fewer days abstinent compared to patients without them.225”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [225]
In the citing paper
“A randomized placebo-controlled trial of modafinil (400mg/d) for CUD indicated significantly lower use compared to placebo, but no significant differences in craving or withdrawal (56), while a larger subsequent trial showed no differences in cocaine use, craving, withdrawal, retention, or abstinence even when accounting for dosage (57).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [56]
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
The measurement of pessimism: the hopelessness scale
Beck, A. T., Weissman, A., Lester, D., & Trexler, L. (1974) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0037562 · Cited by 5,494 · cited 3×
“…were assessed with the Addiction Severity Index (ASI) (McLellan et al, 1992), Hamilton Anxiety Scale (Ham A) (Hamilton, 1969), and Hamilton Depression Scale (Ham D) (Hamilton, 1967), Beck Depression Inventory (BDI) (Beck et al, 1974), and the Symptom Checklist 90 Revised (SCL90) (Derogatis, 1977).”
MethodThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Self-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Diggle, P. J., Heagerty, P. J., Liang, K.-Y., & Zeger, S. L. (2002) · doi:10.1093/oso/9780198524847.001.0001 · Cited by 3,384
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
[Drug addiction and drug abuse].
Feuerlein, W. (1969) · PubMed · Cited by 1,415
Research works printed but not linked: 4
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders—Subject Edition (SCID-I/P, Version 2.0). Biometrics Research Department New York State Psychiatric Institute: New York.
- Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D et al (1992). Cognitive-Behavioral Coping Skills Therapy Manual. US Government Printing Office: Washington, DC.
- Malcolm RJ, Donovan JL, DeVane CL, Elkashef A, Chiang N, Mojsiak J (2002). Influence of Modafinil, 400 or 800 mg/day on Subjective Effects of Intravenous Cocaine in Non-treatment Seeking Volunteers. College on Problems of Drug Dependence: Quebec City.
- Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M (1995). In search of a Universal Drug Craving Scale. Annual Meeting of the American Psychiatric Association: Miami, FL.
Cited by
Items 101–200 of 391
Hypothesis-Driven Medication Discovery for the Treatment of Psychostimulant Addiction
Xi, Z.-X., & Gardner, E. (2008) · Current Drug Abuse Reviewse · doi:10.2174/1874473710801030303 · Cited by 70
“It also significantly blunts the euphorigenic effects of cocaine, reduces daily cocaine use, and prolongs abstinence in human cocaine addicts [324-326].”
BackgroundBehavioral and subjective effects of D-amphetamine and modafinil in healthy adults.
Makris, A. P., Rush, C. R., Frederich, R. C., Taylor, A. C., & Kelly, T. H. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.2.123 · Cited by 68
Cocaine and Sleep: Early Abstinence
MORGAN, P. T., & Malison, R. T. (2007) · The Scientific World JOURNAL · doi:10.1100/tsw.2007.209 · Cited by 71
“Notably, promising candidate pharmacotherapies for cocaine addiction either have effects on sleep or daytime wakefulness/cognition: gamma-vinyl GABA[35], tiagabine[33,34], and topiramate[38] may alter sleep through GABAergic mechanisms; modafinil[39] improves vigilance and appears to alter the homeostatic sleep/wake d…”
BackgroundFreeman, W. M., Lull, M. E., Patel, K. M., Brucklacher, R. M., Morgan, D., Roberts, D. C. S., & Vrana, K. E. (2010) · BMC Neuroscience · doi:10.1186/1471-2202-11-29 · Cited by 73
Future pharmacological treatments for substance use disorders
Forray, A., & Sofuoglu, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04474.x · Cited by 74
Schmitz, J. M., Green, C. E., Stotts, A. L., Lindsay, J. A., Rathnayaka, N. S., Grabowski, J., & Moeller, F. G. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.12.015 · Cited by 65
“, 2009) and gender (Dackis et al., 2012) as sources of variability in treatment outcome.”
BackgroundInfluentialSchmitz, J. M., Rathnayaka, N., Green, C. E., Moeller, F. G., Dougherty, A. E., & Grabowski, J. (2012) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2012.00077 · Cited by 65
“, 2001, 2004) and modafinil (Dackis et al., 2005; Anderson et al., 2009), but each having different dopamine-enhancing mechanisms, were expected to produce more powerful treatment effects when given in combination.”
BackgroundPsychosocial approaches to psychostimulant dependence: A systematic review
Shearer, J. (2006) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2006.06.012 · Cited by 77
Paterson, N. E., Fedolak, A., Olivier, B., Hanania, T., Ghavami, A., & Caldarone, B. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.03.006 · Cited by 66
“Preliminary clinical trials indicated that modafinil may be effective in treating cocaine dependence (Dackis et al., 2005; Hart et al., 2008), although a metaanalysis indicated that modafinil was not effective in reducing cocaine use (Castells et al.”
Modafinil does not serve as a reinforcer in cocaine abusers
Vosburg, S. K., Hart, C. L., Haney, M., Rubin, E., & Foltin, R. W. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.09.002 · Cited by 64
SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues
Cao, J., Prisinzano, T. E., Okunola, O. M., Kopajtic, T. A., Shook, M., Katz, J. L., & Newman, A. H. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1002025 · Cited by 69
Greenwald, M. K., Lundahl, L. H., & Steinmiller, C. L. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.175 · Cited by 65
“Other than this collection of SR-AMP findings, the only other instance of concordance between human laboratory and clinical trial efficacy findings for an anti-cocaine medication has occurred with modafinil (Dackis et al , 2005; Hart et al , 2008; Anderson et al , 2009).”
Garza, R. D. L., Zorick, T. S., London, E. D., & Newton, T. F. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.08.013 · Cited by 65
“Modafinil reduced the euphoric effects produced by intravenous cocaine (Dackis et al., 2003), reduced smoked cocaine self-administration and associated subjective effects (Hart et al., 2008), and reduced cocaine use in a double-blind, placebo-controlled clinical trial (Dackis et al., 2005).”
BackgroundKalechstein, A. D., Mahoney, J. J., Yoon, J. H., Bennett, R., & Garza, R. D. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.064 · Cited by 66
“Finally, it is worth mentioning that modafinil has shown some efficacy as a treatment for cocaine-dependence (Dackis et al., 2005, 2003, 2012).”
BackgroundNew Drugs, Old Targets: Tweaking the Dopamine System to Treat Psychostimulant Use Disorders
Newman, A. H., Ku, T. C., Jordan, C. J., Bonifazi, A., & Xi, Z. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-124205 · Cited by 67
McElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802342907 · Cited by 61
“Following Dackis’ (9) encouraging preliminary results using modafinil for cocaine abuse, we chose this medication to accompany time limited structured psychotherapy in a pilot treatment study.”
BackgroundInfluentialNewton, T. F., Reid, M. S., De La Garza, R., Mahoney, J. J., Abad, A., Condos, R., Palamar, J., Halkitis, P. N., Mojisak, J., Anderson, A., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009097 · Cited by 61
Goudriaan, A. E., Veltman, D. J., van den Brink, W., Dom, G., & Schmaal, L. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.04.006 · Cited by 64
Pharmacological strategies for detoxification
Diaper, A., Law, F. D., & Melichar, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12245 · Cited by 68
Agonist Replacement for Stimulant Dependence: A Review of Clinical Research
Stoops, W., & Rush, C. (2013) · Current Pharmaceutical Design · doi:10.2174/138161281940131209142843 · Cited by 60
DeVito, E. E., Babuscio, T. A., Nich, C., Ball, S. A., & Carroll, K. M. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.10.007 · Cited by 64
“Similarly, RCTs of modafinil (157M, 53F; Dackis et al., 2012) and naltrexone plus CBT or medication management (116M, 48F; Pettinati et al., 2008 reported improved cocaine outcomes in men relative to placebo, but women tended towards worse outcomes on medication relative to placebo, even after…”
BackgroundResultInfluentialGonzález, B., Raineri, M., Cadet, J. L., García‐Rill, E., Urbano, F. J., & Bisagno, V. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.02.002 · Cited by 63
“The use of modafinil as a treatment for cocaine and METH dependence remains inconclusive, with studies showing positive outcomes (Dackis et al., 2005; McGough et al., 2009) and studies showing promising but yet non-significant results in reducing drug use (Dackis et al, 2012; Neuropharmacology.”
ResultShorter, D. I., Domingo, C. B., & Kosten, T. R. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.985203 · Cited by 64
“compared modafinil (at 200 and 400 mg/day) and placebo, with all medication conditions receiving once-weekly cognitive behavioral therapy [123].”
BackgroundPharmacotherapy of Addictive Disorders
Ross, S., & Peselow, E. D. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181a91655 · Cited by 65
“Several small clinical trials have suggested a role in promoting cocaine abstinence for modafinil(166,167) with a double-blind placebocontrolled trial associated with good treatment retention and prolonged abstinence from cocaine compared with placebo.(167)”
BackgroundMonoamine Transporter Inhibitors and Substrates as Treatments for Stimulant Abuse
Howell, L. L., & Negus, S. S. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-420118-7.00004-4 · Cited by 63
“…al., 2009; Dackis, Kampman, Lynch, Pettinati, & O’Brien, 2005; Dackis et al., 2003; Hart, Haney, Vosburg, Rubin, & Foltin, 2008), although a recent study did not find a significant main effect of modafinil on the rate or duration of cocaine use in cocaine-dependent patients (Dackis et al., 2012).”
The current clinical knowledge on the treatment of gambling disorder: A summary
Hloch, K., Mladěnka, P., Doseděl, M., Adriani, W., & Zoratto, F. (2017) · Synapse · doi:10.1002/syn.21976 · Cited by 56
Sahakian, B. J., & Morein-Zamir, S. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00004-8 · Cited by 54
Reinforcing effects of stimulants in humans: Sensitivity of progressive-ratio schedules.
Stoops, W. W. (2008) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0013657 · Cited by 54
Haile, C. N., Mahoney, J. J., Newton, T. F., & Garza, R. D. L. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.010 · Cited by 60
“…been demonstrated on cocaine reinforcement in animals, modafinil attenuates the positive subjective and reinforcing effects produced by cocaine in the laboratory (Dackis et al., 2003; Malcolm et al., 2006; Hart et al., 2008; De La Garza et al., 2011) and reduces cocaine use (Dackis et al., 2005).”
Addictive potential of modafinil and cross‐sensitization with cocaine: a pre‐clinical study
Wuo‐Silva, R., Fukushiro, D. F., Borçoi, A. R., Fernandes, H. A., Procópio‐Souza, R., Hollais, A. W., Santos, R., Ribeiro, L. T. C., Corrêa, J. M. R. M., Talhati, F., et al. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00341.x · Cited by 53
“Modafinil has also been investigated for use in cocaine addiction (Dackis et al. 2005; Hart et al. 2008; Haney 2009).”
BackgroundAgonist Replacement Therapy for Cocaine Dependence: A Translational Review
Rush, C. R., & Stoops, W. W. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.184 · Cited by 56
Pharmacological Treatments for Cocaine Dependence: Is There Something New?
Karila, L., Reynaud, M., Aubin, H., Rolland, B., Guardia, D., Cottencin, O., & Benyamina, A. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150873 · Cited by 55
“A randomized, double-blind clinical trial involved 62 cocainedependent outpatients who received either modafinil 400 mg/day or placebo for 8 weeks in conjunction with CBT [54].”
MethodMcClure, E. A., Sonne, S. C., Winhusen, T., Carroll, K. M., Ghitza, U. E., McRae-Clark, A. L., Matthews, A. G., Sharma, G., Van Veldhuisen, P., Vandrey, R. G., et al. (2014) · Contemporary Clinical Trials · doi:10.1016/j.cct.2014.08.011 · Cited by 50
Joos, L., Goudriaan, A. E., Schmaal, L., Fransén, E., van den Brink, W., Sabbe, B., & Dom, G. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.10.004 · Cited by 59
“…modafinil demonstrated promising treatment effects in cocaine and methamphetamine dependent patients with significant more negative urine samples (Dackis et al., 2005; Shearer et al., 2009), longer periods of abstinence (Dackis et al., 2005; Anderson et al., 2009), a reduction of substance use…”
InfluentialAn Analysis of UK Drug Policy A Monograph Prepared for the UK Drug Policy Commission
Reuter, P., & Stevens, A. (2007) · Cited by 71
Treatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
“mg/day) was shown to reduce craving and increase cocaine abstinence compared to placebo (total N=272) (Anderson et al., 2009; Dackis et al., 2005).”
BackgroundBanks, M. L., Hutsell, B. A., Schwienteck, K. L., & Negus, S. S. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0042-9 · Cited by 52
What’s New in the Treatment of Cocaine Addiction?
Kampman, K. M. (2010) · Current Psychiatry Reports · doi:10.1007/s11920-010-0143-5 · Cited by 53
Self-citationMahler, S. V., Hensley-Simon, M., Tahsili-Fahadan, P., LaLumiere, R. T., Thomas, C., Fallon, R. V., Kalivas, P. W., & Aston-Jones, G. (2014) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00506.x · Cited by 48
“…result in part from elevating extrasynaptic glutamate, thereby stimulating accumbens mGluR2/3s. Previous clinical work has indicated that modafinil might be useful in treating at least some cases of stimulant abuse in humans (Dackis et al. 2003, 2005; Hart et al. 2008; Anderson et al. 2009).”
InfluentialTahsili‐Fahadan, P., Carr, G. V., Harris, G. C., & Aston‐Jones, G. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.94 · Cited by 48
“Although it has been shown that modafinil reduces craving for cocaine (Hart et al , 2008), a recent preclinical study reported that modafinil (128 mg/kg) alone can reinstate an extinguished CPP for cocaine (Bernardi et al , 2009); note, though, that the effects of modafinil pretreatment on…”
McCann, D. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100503 · Cited by 46
Modafinil and sleep architecture in an inpatient–outpatient treatment study of cocaine dependence
Morgan, P. T., Angarita, G. A., Canavan, S., Pittman, B., Oberleitner, L., Malison, R. T., Mohsenin, V., Hodges, S., Easton, C., McKee, S., et al. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.12.004 · Cited by 46
“Another study (Dackis et al., 2012) examined only non-alcohol ependent chronic cocaine users, but failed to replicate earlier esults with regard to %negative urine frequency.”
BackgroundMethodThe use of stimulant medications for non-core aspects of ADHD and in other disorders
Sinita, E., & Coghill, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.014 · Cited by 53
Verrico, C. D., Haile, C. N., Mahoney III, J. J., Thompson-Lake, D. G. Y., Newton, T. F., & De La Garza II, R. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.05.008 · Cited by 44
“Further, modafinil significantly reduced cocaine-positive urines in an outpatient clinical trial (Dackis et al., 2005), and while two larger subsequent clinical trials of modafinil were negative (considering group means), modafinil reduced cocaine-positive urines in subsets of participants -…”
BackgroundMcCreary, A. C., Müller, C. P., & Filip, M. (2015) · International review of neurobiology · doi:10.1016/bs.irn.2015.02.008 · Cited by 53
Sleep architecture, cocaine and visual learning
Morgan, P. T., Pace‐Schott, E. F., Sahul, Z. H., Coric, V., Stickgold, R., & Malison, R. T. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02233.x · Cited by 43
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42
Cognitive control and the dopamine D2-like receptor: a dimensional understanding of addiction
Groman, S. M., & Jentsch, J. D. (2011) · Depression and Anxiety · doi:10.1002/da.20897 · Cited by 49
A review of the use of modafinil for attention-deficit hyperactivity disorder
Turner, D. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.4.455 · Cited by 40
Pharmacotherapy for smoking cessation: present and future
Aubin, H.-J., Karila, L., & Reynaud, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796150837 · Cited by 39
“Modafinil is marketed as a wakefulness-promoting agent for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder [120] Because of its shown efficacy in cocaine dependence [121], and its clinical effects that may alleviate nicotine withdrawal symptoms [122], modafinil h…”
BackgroundBehavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys.
Newman, J. L., Negus, S. S., Lozama, A., Prisinzano, T. E., & Mello, N. K. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021042 · Cited by 44
“…to (a) doses used clinically to promote wakefulness in humans (100–600 mg, or approximately 1.5–9 mg/kg), and (b) doses that decrease cocaine consumption in human laboratory and outpatient studies (200–400 mg, or approximately 3–8 mg/kg; Dackis et al., 2005; Hart et al., 2008; Stoops et al., 2005).”
InfluentialDrugs currently in Phase II clinical trials for cocaine addiction
Kim, J. H., & Lawrence, A. J. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.915312 · Cited by 44
“to assess modafinil’s clinical efficacy demonstrated that 400 mg of modafinil administered daily over 8 weeks, accompanied with cognitive behavioural therapy (CBT) twice weekly significantly increased the average percentage of people who gave cocaine-negative urine samples compared to placebo (42 vs 24%;mean differenc…”
BackgroundMooney, M. E., Schmitz, J. M., Moeller, F. G., & Grabowski, J. G. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.10.011 · Cited by 41
“…including disulfiram and modafinil, may work in part by facilitating dopaminergic functioning, either directly by inhibiting dopamine beta hydroxylase (disulfiram) or indirectly by enhancing glutamate function (modafinil) (Carroll et al., 2004a; Dackis et al., 2005; Petrakis et al., 2000).”
BackgroundStoops, W. W., Blackburn, J. W., Hudson, D. A., Hays, L. R., & Rush, C. R. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.07.005 · Cited by 40
“…utility of atomoxetine for stimulant use disorders remains unclear, although the use of other agonist-type medications (e.g., modafinil, d-amphetamine, methylphenidate) has proven effective in managing stimulant dependence (Dackis et al., 2005; Grabowski et al., 2001 2004; Tiihonen et al., 2007).”
BackgroundSmart drugs and neuroenhancement: what do we know?
Esposito, M., Cocimano, G., Ministrieri, F., Rosi, G. L., Nunno, N. R. D., Messina, G., Sessa, F., & Salerno, M. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4948 · Cited by 50
Lile, J. A., Stoops, W. W., Durell, T. M., Glaser, P. E. A., & Rush, C. R. (2006) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.14.2.136 · Cited by 38
Clinical management of psychostimulant withdrawal: review of the evidence
Li, M. J., & Shoptaw, S. J. (2023) · Addiction · doi:10.1111/add.16093 · Cited by 39
Mereu, M., Chun, L. E., Prisinzano, T. E., Newman, A. H., Katz, J. L., & Tanda, G. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13376 · Cited by 39
“Recent clinical trials have shown promising results for modafinil as a treatment for stimulant use disorders (Dackis et al., 2005; Hart et al., 2008; Anderson et al., 2009; Heinzerling et al., 2010; Kampman et al., 2015).”
BackgroundThe principles of agonist pharmacotherapy for psychostimulant dependence
SHEARER, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801927372 · Cited by 37
A review of psychological and pharmacological treatment options for methamphetamine dependence
Ciketic, S., Hayatbakhsh, M. R., Doran, C. M., Najman, J. M., & McKetin, R. (2012) · Journal of Substance Use · doi:10.3109/14659891.2011.592900 · Cited by 36
Novel medications to treat addictive disorders
Montoya, I. D., & Vocci, F. J. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0063-9 · Cited by 47
Modafinil Treatment of Cocaine Dependence: A Systematic Review and Meta-Analysis
Sangroula, D., Motiwala, F., Wagle, B., Shah, V. C., Hagi, K., & Lippmann, S. (2017) · Substance Use & Misuse · doi:10.1080/10826084.2016.1276597 · Cited by 36
“These psychosocial approaches evidenced disappointing clinical outcomes because most of the subjects were unable to resist cocaine craving or euphoria (Dackis et al., 2012).”
BackgroundTreatment of addictive behaviors in liver transplant patients
Weinrieb, R. M., & Lucey, M. R. (2007) · Liver Transplantation · doi:10.1002/lt.21340 · Cited by 36
“In general, treatment of cocaine dependence is difficult, with only moderate success rates; however, recent research suggests that modafinil, a drug used to treat narcolepsy, when combined with cognitive behavioral therapy, enhances cocaine abstinence.(24) We believe an active cocaine user should not be considered for…”
ResultThe Search for Medications to Treat Stimulant Dependence
Kampman, K. M. (2008) · Addiction Science & Clinical Practice · doi:10.1151/ascp084228 · Cited by 41
Self-citationHidden Markov models for zero‐inflated Poisson counts with an application to substance use
DeSantis, S. M., & Bandyopadhyay, D. (2011) · Statistics in Medicine · doi:10.1002/sim.4207 · Cited by 37
Lee, N., Pennay, A. E., Hester, R., McKetin, R., Nielsen, S., & Ferris, J. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00473.x · Cited by 36
“Two RCTs of cocaine dependence have shown that modafinil-treated patients are more likely to abstain from cocaine compared with those receiving placebo [19,20].”
BackgroundPharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications
Verrico, C. D., Haile, C. N., Newton, T. F., Kosten, T. R., & Garza, R. D. L. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.836488 · Cited by 37
“A preliminary outpatient clinical trial found that compared to placebo, modafinil (400 mg/day) decreased cocaine-positive urines [73].”
BackgroundResultAdvances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Poulet, E., Brunelin, J., Kallel, L., d’Amato, T., & Saoud, M. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07060868 · Cited by 35
The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic
Zhang, H., Bi, G., Yang, H.-J., He, Y., Xue, G., Cao, J., Tanda, G., Gardner, E. L., Newman, A. H., & Xi, Z. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.41 · Cited by 37
“…et al, 2006; McGregor et al, 2008; Shearer et al, 2009; Verrico et al, 2014), although several others failed to confirm the therapeutic efficacy of (±)MOD in treatment of cocaine (Dackis et al, 2012) or methamphetamine dependence in larger cohorts (Anderson et al, 2012; Heinzerling et al, 2010).”
ResultPérez-Mañá, C., Castells, X., Vidal, X., Casas, M., & Capellà, D. (2011) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2010.08.012 · Cited by 33
A placebo-controlled trial of modafinil for nicotine dependence
Schnoll, R. A., Wileyto, E. P., Pinto, A., Leone, F. T., Gariti, P., Siegel, S. J., Perkins, K. A., Dackis, C. A., Heitjan, D. F., Berrettini, W. H., et al. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.04.008 · Cited by 35
“Modafinil is FDA approved to treat sleep disorders (Ballon and Feifel, 2006), and it has been evaluated as a treatment for cocaine dependence (Dackis et al., 2005) and ADHD (Lindsay et al.”
BackgroundInfluentialSelf-citationShuman, T., Cai, D. J., Sage, J. R., & Anagnostaras, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.07.039 · Cited by 36
Attenuated methamphetamine induced neurotoxicity by modafinil administration in mice
Raineri, M., Peskin, V., Goitia, B., Taravini, I. R. E., Giorgeri, S., Urbano, F. J., & Bisagno, V. (2011) · Synapse · doi:10.1002/syn.20943 · Cited by 33
“Modafinil blunts the reinforcing as well as cardiovascular effects of cocaine and decreases cocaine use and relapse rates in cocaine addicts (Dackis et al., 2005; Hart et al., 2008).”
BackgroundPsychostimulant drugs for cocaine dependence
Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007380.pub4 · Cited by 110
Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review
Lassi, D. L. S., Malbergier, A., Negrão, A. B., Florio, L., Aquino, J. P. D., & Castaldelli-Maia, J. M. (2022) · Brain Sciences · doi:10.3390/brainsci12111546 · Cited by 36
“, 2005, USA [43] 62; 44; 44:16; Y; O; 8 weeks intervention + 1-week observation; Cocaine dependence (DSM-IV); S; C Brief Substance Craving Scale (BSCS); Cocaine Craving Questionnaire (CCQ) Oral modafinil 400 mg or placebo daily for 8 weeks; twice-weekly cognitive behavioral therapy BCSC, CCQ: no significant treatment…”
MethodVelázquez-Sánchez, C., Ferragud, A., Hernández‐Rabaza, V., Nácher, A., Merino, V., Cardá, M., Murga, J., & Canales, J. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.78 · Cited by 34
Neuroimaging and drug taking in primates
Murnane, K. S., & Howell, L. L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2222-7 · Cited by 37
“Consistent with the importance of subjective effects in drug taking, a number of clinical studies suggest that modafinil may improve the clinical outcomes for treatment of cocaine dependence by reducing self-reports of craving and cocaine-induced euphoria (Anderson et al. 2009; Dackis et al. 2005; Dackis et al. 2003;…”
Nuijten, M., Blanken, P., van den Brink, W., Goudriaan, A. E., & Hendriks, V. M. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645268 · Cited by 34
“Of these agents, the psychostimulant modafinil has shown promising effects, in terms of increased and protracted cocaine abstinence, in several studies (Anderson et al., 2009; Dackis et al., 2005; Kampman et al., 2015); however, in a recent randomised controlled study in crackcocaine dependent patients, we found that…”
ResultOpen-Label Pilot Study of Modafinil for Methamphetamine Dependence
McGaugh, J., Mancino, M. J., Feldman, Z., Chopra, M. P., Gentry, W. B., Cargile, C., & Oliveto, A. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181b591e0 · Cited by 31
Patin, A., & Hurlemann, R. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-16522-6_10 · Cited by 42
A Retrospective Review of Supratherapeutic Modafinil Exposures
Carstairs, S. D., Urquhart, A. G., Hoffman, J., Clark, R. F., & Cantrell, F. L. (2010) · Journal of Medical Toxicology · doi:10.1007/s13181-010-0017-6 · Cited by 31
“It has also shown promise in the treatment of cocaine dependence and withdrawal [6–8], alcoholic organic brain disorder [9, 10], and in augmentation of antidepressant regimens [11].”
BackgroundGlutamatergic Neuroplasticity in Cocaine Addiction
Uys, J. D. K., & Reissner, K. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-385506-0.00009-0 · Cited by 32
Promising Medications for Cocaine Dependence Treatment
Somaini, L., Donnini, C., Raggi, M. A., Amore, M., Ciccocioppo, R., Saracino, M. A., Kallupi, M., Malagoli, M., Gerra, M. L., & Gerra, G. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488911795933893 · Cited by 32
“[48].”
Nonhuman Primate Positron Emission Tomography Neuroimaging in Drug Abuse Research
Howell, L. L., & Murnane, K. S. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136689 · Cited by 30
Dahl, J. P., Kampman, K. M., Oslin, D. W., Weller, A. E., Lohoff, F. W., Ferraro, T. N., Brien, C. P. O., & Berrettini, W. H. (2005) · Psychiatric Genetics · doi:10.1097/00041444-200512000-00010 · Cited by 29
“treatment of cocaine dependence and are currently being studied in clinical trials for the treatment of cocaine addiction (Touret et al., 1994; Ferraro et al., 1997; White, 1997; Angehagen et al., 2003; Dackis and O’Brien, 2003; Dackis et al., 2004; Gorelick et al., 2004; Kaminski et al., 2004; Kampman et al., 2004).”
MethodSelf-citationPreliminary evidence for normalization of risk taking by modafinil in chronic cocaine users
Canavan, S. V., Forselius, E., Bessette, A. J., & MORGAN, P. T. (2014) · Addictive Behaviors · doi:10.1016/j.addbeh.2014.02.015 · Cited by 31
Pérez, L. J. G., Cardullo, S., Cellini, N., Sarlo, M., Monteanni, T., Bonci, A., Terraneo, A., Gallimberti, L., & Madeo, G. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02568-2 · Cited by 29
Schmitz, J. M., Stotts, A. L., Vujanovic, A. A., Weaver, M. F., Yoon, J. H., Vincent, J. N., & Green, C. E. (2017) · Contemporary Clinical Trials · doi:10.1016/j.cct.2017.12.015 · Cited by 28
Recent advances in the pharmacotherapy of cocaine dependence
Dackis, C. A. (2004) · Current Psychiatry Reports · doi:10.1007/s11920-004-0018-8 · Cited by 29
Self-citationADHD with comorbid substance use disorder: review of treatment
Magon, R., & Müller, U. (2012) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.111.009340 · Cited by 31
“A double-blind, placebo-controlled trial in 62 cocaine-dependent men and women reported increased cocaine abstinence in the modafinil group (Dackis 2005).”
BackgroundThe cognitive cost of reducing relapse to cocaine-seeking with mGlu5 allosteric modulators
Gobin, C. M., & Schwendt, M. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05351-8 · Cited by 28
Use of stimulants to treat cocaine and methamphetamine abuse
Moeller, F. G., Schmitz, J. M., Herin, D. V., & Kjome, K. L. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0062-x · Cited by 26
Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Szobot, C. M., & Bukstein, O. G. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2007.11.003 · Cited by 35
“2004), an effect noted in a follow-up study in patients with ADHD (Dackis et al. 2005).”
BackgroundPredictors of Enrollment in a Smoking Cessation Clinical Trial After Eligibility Screening
Dahm, J. L., Cook, E., Baugh, K., Wileyto, E. P., Pinto, A., Leone, F. T., Halbert, C. H., & Schnoll, R. A. (2009) · Journal of the National Medical Association · doi:10.1016/s0027-9684(15)30931-7 · Cited by 31
Psychostimulant Use Disorder, an Unmet Therapeutic Goal: Can Modafinil Narrow the Gap?
Hersey, M., Bacon, A. K., Bailey, L. G., Coggiano, M. A., Newman, A. H., Leggio, L., & Tanda, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.656475 · Cited by 25
Evidence-Based Treatments of Addiction
O’Brien, C. P. (2011) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.9.1.foc107 · Cited by 26
Self-citationEpigenetic Regulatory Dynamics in Models of Methamphetamine-Use Disorder
Jayanthi, S., McCoy, M. T., & Cadet, J. L. (2021) · Genes · doi:10.3390/genes12101614 · Cited by 23
“Modafinil has also been used in clinical trials for treatment of cocaine [60,61] and METH dependence [62].”
MethodNuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115582151 · Cited by 23
“…cocaine-positive urine (Ahmadi et al., 2009; Kampman et al., 2001; Poling et al., 2007; Sofuoglu et al., 2003), cocaine craving (Sinha et al., 2006; Weiss et al., 1997), concurrent alcohol use (Alterman et al., 2000; Anderson et al., 2009; Poling et al., 2007) and gender (Dackis et al., 2012).”
BackgroundResultRamachandra, B. (2016) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2016.1153948 · Cited by 23
“Recent studies have found that modafinil may help recovering cocaine addicts fight their addiction (Dackis et al., 2005; Martinez-Raga et al., 2008).”
Background
Metadata
- Authors
- Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Dackis, Charles A
- Venue
- Neuropsychopharmacology
- Published
- 2004-11-03
- Volume
- 30
- Issue
- 1
- Pages
- 205-211
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1966136869
- Cited by
- 391
- References
- 44
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 21 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 26
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60da005186-25)
- National Institute on Drug Abuse (DA P60-05186, DA P50-12756, P50DA012756)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- modafinil, cocaine dependence, cocaine abstinence, cognitive behavioral therapy, psychosocial interventions, cocaine craving, cocaine withdrawal, medication-assisted treatment, African American patients
- MeSH terms
- Modafinil, Adult, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Compliance, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Treatment Outcome, Sample Size, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.